Apple v. ITC (24-1285): Federal Circuit Affirms Wearable Sensor Patent Rulings
Apple challenged International Trade Commission rulings across five patents covering multi-wavelength physiological monitoring sensors used in the Apple Watch. The Federal Circuit affirmed the outcome after 814 days of appellate proceedings. The case touches core wearable health-sensing IP that remains commercially critical.
Apple's Federal Circuit appeal over five wearable sensor patents — affirmed
Apple, Inc. filed this appeal at the Court of Appeals for the Federal Circuit on 26 December 2023, challenging rulings by the International Trade Commission across five patents: US10912502B2, US10687745B1, US7761127B2, US10945648B2, and US10912501B2. The patents collectively cover multi-wavelength sensor substrates, physiological monitoring devices and methods, and user-worn devices for noninvasively measuring physiological parameters — technology at the heart of Apple Watch's blood oxygen sensing functionality.
The recorded basis of termination is 'Appeal Dismissed'; the docket order states the cause was considered and it is 'ORDERED AND ADJUDGED: AFFIRMED.' The Federal Circuit's order affirms the ITC's underlying determination, leaving the Commission's position intact. The specific terms and scope of the ITC's original determination are not reproduced in the available appellate record.
An 814-day appellate timeline is consistent with complex multi-patent ITC appeals involving substantial briefing and potentially oral argument. What drove the Federal Circuit's affirmance — whether claim construction, obviousness, or exclusion order scope — is not specified in the available public record. The absence of a reversal or remand means the ITC's determination stands without modification from the appellate court.
See Complete Case & Patent Analysis →Filing to Appeal Dismissed in 814 days
814 days — above the median duration for Federal Circuit patent appeals
US10912502B2 and four further patents — wearable physiological monitoring sensors
Any company designing, manufacturing, or importing wearable devices that incorporate multi-wavelength optical sensors for noninvasive physiological monitoring — including blood oxygen, heart rate, or related biometric measurement — should treat these five patents as priority FTO targets. The Federal Circuit's affirmance means they carry reinforced legal weight. Medical wearable startups, consumer electronics OEMs, and component suppliers in the sensor substrate space are all potentially within scope.
Official order — verbatim text
The Federal Circuit's order — 'ORDERED AND ADJUDGED: AFFIRMED' — is a merits affirmance indicating the court reviewed the ITC's determinations on the five asserted physiological monitoring patents and found no reversible legal error. The recorded basis of termination is 'Appeal Dismissed'; the docket order text states AFFIRMED. The specific grounds of affirmance — whether claim construction, obviousness, or exclusion order scope — are not detailed in the available public record.
Federal Circuit affirms: what the ruling means for both parties
What 'AFFIRMED' means at the Federal Circuit
An affirmance at the Federal Circuit means the appellate court found no reversible error in the ITC's underlying determination. The lower tribunal's ruling stands in full. Apple's challenge to the ITC's position on all five asserted patents was unsuccessful at this appellate level. The Federal Circuit does not retry facts — it reviews for legal error, claim construction mistakes, or procedural irregularities.
No reversible error foundITC's determination survives Federal Circuit scrutiny
As the appellee, the ITC prevails. Its determination on all five physiological monitoring patents is affirmed and carries full weight. For Apple, the affirmance means its appellate challenge has been exhausted at this level. Whether the underlying ITC determination favoured or constrained Apple's product rights depends on the ITC's original ruling, which is not reproduced in the available appellate record.
ITC position upheldApple's appellate options exhausted at Federal Circuit level
Apple, as appellant, did not prevail. Following an affirmance, further federal appellate review would require a petition for certiorari to the Supreme Court — a discretionary and rarely granted avenue. The five patents covering Apple Watch wearable sensor technology remain subject to whatever ITC determination the Federal Circuit has now affirmed, raising the bar for any future challenge to those holdings.
Supreme Court petition only remaining routeWearable health sensor IP landscape: post-affirmance risk
This affirmance strengthens the persuasive weight of the ITC's determinations on multi-wavelength physiological sensing patents. Competitors designing or importing wearable health monitoring devices that may read on US10912502B2, US10687745B1, US7761127B2, US10945648B2, or US10912501B2 face a higher challenge bar following the Federal Circuit's endorsement. Product teams and IP counsel in the wearables sector should treat these patents as having reinforced enforceability signals.
Elevated enforcement risk for sectorFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Apple, Inc. | Company | /Search in Eureka ↗ |
| Defendant | International Trade Commission | Company | /Search in Eureka ↗ |
| Plaintiff counsel | David P. Yin | Attorney | Counsel for Apple, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Derek Anthony Gosma | Attorney | Counsel for Apple, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Joseph J. Mueller | Attorney | Counsel for Apple, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Mark D. Selwyn | Attorney | Counsel for Apple, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Sarah R. Frazier | Attorney | Counsel for Apple, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Thomas Gregory Sprankling | Attorney | Counsel for Apple, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Wilmer Cutler Pickering Hale & Dorr LLP | Law Firm | Representing Apple, Inc.Search in Eureka ↗ |
| Defendant counsel | Houda Morad | Attorney | Counsel for International Trade CommissionSearch in Eureka ↗ |
| Defendant counsel | Margaret D. Macdonald | Attorney | Counsel for International Trade CommissionSearch in Eureka ↗ |
| Defendant counsel | Michelle W. Klancnik | Attorney | Counsel for International Trade CommissionSearch in Eureka ↗ |
| Defendant counsel | Ronald Traud | Attorney | Counsel for International Trade CommissionSearch in Eureka ↗ |
| Defendant law firm | International Trade Commission | Law Firm | Representing International Trade CommissionSearch in Eureka ↗ |
| Defendant law firm | United States International Trade Commission | Law Firm | Representing International Trade CommissionSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
R&D signals in the wearable physiological monitoring sensor space
Forward-looking patent and innovation intelligence derived from Apple's five-patent ITC enforcement campaign — critical reading for R&D teams in wearable health and biosensor technology.
Apple's physiological sensing patent portfolio: filing trends
Apple's enforcement of five distinct physiological monitoring patents — spanning substrates, devices, and methods — suggests a deep and layered portfolio in wearable health sensing. R&D teams should map Apple's full continuation and divisional filing activity in multi-wavelength optical sensing to anticipate where new patent coverage is being built around next-generation biosensor architectures.
Apple biosensor IP depthMulti-wavelength optical sensing: global patent filing activity
The five asserted patents reflect a broader surge in filings around noninvasive optical physiological monitoring. Tracking global publication trends for multi-wavelength photoplethysmography and pulse oximetry sensor substrates reveals which players are building offensive portfolios and where the claim density is highest — critical intelligence for anyone developing wearable health hardware.
Sensor filing surgeITC respondents in wearable health: patent counter-positioning
Companies drawn into ITC proceedings over wearable physiological monitoring IP typically accelerate their own defensive and offensive patent filing in adjacent sensor architectures. Tracking patent activity by parties that have faced Apple ITC actions — or that operate in the same biosensor space — surfaces competitive counter-positioning strategies and potential design-around opportunities.
Defensive portfolio signalsAdjacent claim white space near Apple's monitoring sensor patents
Apple's five-patent cluster focuses on specific substrate configurations and device-level architectures. White space may exist in adjacent areas such as algorithmic signal processing for noninvasive monitoring, flexible or textile-integrated sensor form factors, and continuous glucose or hydration sensing — domains where the asserted claim scope is thinner and where novel filings may establish defensible IP positions.
Innovation opportunitySimilar Federal Circuit appeals: wearable sensor and ITC patent cases
Explore Federal Circuit appeals involving ITC determinations on wearable physiological monitoring and biosensor patents — cases most directly comparable to Apple v. ITC (24-1285).
What this case signals for the wearable health sensor IP landscape
Five physiological monitoring patents affirmed at the Federal Circuit. Here is what IP teams in the wearables sector need to act on now.
Multi-patent ITC appeals carry compounded appellate risk
Apple's challenge across five patents in a single Federal Circuit appeal is consistent with ITC practice where multiple patents are consolidated. An affirmance across the board — rather than a mixed outcome — suggests the appellate record supported the Commission's reasoning uniformly. IP teams defending or challenging multi-patent ITC determinations should model this as a realistic outcome scenario.
Wearable physiological sensing patents are now harder to challenge at appeal
The Federal Circuit's affirmance raises the persuasive weight of the ITC's underlying claim constructions and invalidity or infringement determinations on noninvasive monitoring technology. Competitors in the biosensor and smartwatch space should audit their FTO position against all five affirmed patents before next product release cycles.
Apple v International — key questions answered
The Federal Circuit affirmed the ITC's determination. The docket order states 'ORDERED AND ADJUDGED: AFFIRMED,' meaning the appellate court found no reversible error in the Commission's rulings on all five asserted physiological monitoring patents. The recorded basis of termination is 'Appeal Dismissed.' The specific grounds of affirmance are not detailed in the available public record.
Apple asserted five patents: US10912502B2, US10687745B1, US7761127B2, US10945648B2, and US10912501B2. These cover multi-wavelength sensor substrates, physiological monitoring devices and methods, and user-worn devices for noninvasive physiological parameter measurement — technology associated with wearable health monitoring devices such as the Apple Watch.
The affirmance means the ITC's underlying determination on all five patents stands without modification. Apple's challenge was unsuccessful at the Federal Circuit. The patents' enforceability implications depend on the content of the ITC's original determination, which is not reproduced in the available appellate record. Further challenge would require a Supreme Court certiorari petition.
The case was filed on 26 December 2023 and closed on 19 March 2026, a duration of 814 days. This is consistent with — and at the longer end of — timelines for complex multi-patent Federal Circuit appeals involving ITC determinations, which typically involve substantial appellate briefing and, in many cases, oral argument.
The affirmance raises the persuasive weight of these patents. Companies designing or importing wearable physiological monitoring devices incorporating multi-wavelength optical sensors should treat all five patents as priority freedom-to-operate targets. ITC proceedings carry exclusion order exposure for importers, and the Federal Circuit's endorsement of the ITC's position means that exposure remains in force. Specific enforcement consequences depend on the ITC's underlying orders, details of which are not disclosed in the available appellate record.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.